Efficacy and safety of a galactagogue containing Sylimarin and Galega in mothers of preterm infants

Efficacy and safety of a galactagogue containing Sylimarin and Galega in mothers of preterm infants - Galactagogue usefulness in mothers of preterm infants

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010306

Enrollment

100

Registered

2013-03-25

Start date

2013-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prematurity

Interventions

Galactagogue administration from the 3rd to the 28th day of life Placebo administration from the 3rd to the 28th day of life

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: gestational age between 27+0 and 32+6 weeks

Exclusion criteria

Exclusion criteria: breast milk contraindication, lactose intolerance

Design outcomes

Primary

Measure	Time frame
To increase breast milk production by 25% in the treated arm compared with the placebo	—

Countries

Europe

Contacts

Public ContactEnrico Zecca

Catholic University of the Sacred Heart Neonatology

enrizecca@rm.unicatt.it+39630154169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026